secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001564590-21-043969
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.
- R&D expenses $19.7M vs $9.2M YoY; G&A expenses $4.1M vs $2.0M YoY; loss from operations $23.8M vs $11.1M YoY.
- Lead program BDC-1001 Phase 1/2 data update expected in 2H 2021; Phase 2 monotherapy and combo dose-escalation to initiate in 2H 2021.
- Announced R&D collaboration with Genmab for bispecific ISACs: $10M upfront + $15M equity investment; Genmab fully funds three programs through initial proof-of-concept.
- Expanded leadership: added VPs in Clinical Development, Early Development, Biometrics, Program Management, HR, and Communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/0001564590-21-043969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000156459021043969/bolt-8k_20210812.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer